

First reports of adverse drug reactions in recent weeks

© Springer International Publishing Switzerland 2015

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by the drug safety alerting service *Reactions Weekly*. An event is serious (US FDA Med-Watch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment

or damage. *Reactions* and the customized *Reactions Pharmacovigilance Service* are produced by Adis, and monitor >4000 journals, as well as companion journal supplements, major scientific meetings, newsletters from national centres participating in the WHO International Drug Monitoring Programme, media releases, pharmaceutical company websites, and regulatory agency websites.

Table 1 First published reports of adverse drug reactions recently identified by *Reactions Weekly*

Drug and adverse reaction	References
Alectinib: interstitial lung disease (serious)	Ikeda S, Yoshioka H, Arita M, et al. Interstitial lung disease induced by alectinib (CH5424802/RO5424802). <i>Jpn J Clin Oncol</i> . 2015;45(2):221–4. doi:10.1093/jjco/hyu183
Benznidazole: acute generalized exanthematous pustulosis (serious)	Álava-Cruz C, Rojas Perez-Ezquerria P, Pelta-Fernández R, et al. Acute generalized exanthematous pustulosis due to benznidazole. <i>J Allergy Clin Immunol Pract</i> . 2014;2(6):800–2. doi:10.1016/j.jaip.2014.08.003
Dexamethasone/vandetanib: interaction leading to osteonecrosis and focal physal fusion in a child (serious)	Kaste SC, Kaufman RA, Gajjar A, et al. Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors. <i>Pediatr Blood Cancer</i> . 2013;60(9):1552–6. doi:10.1002/pbc.24536
Gefitinib: erysipelas (serious)	Kita T, Nishijima C, Inaoki M, et al. A case of erysipelas in a non-small-cell lung cancer patient receiving gefitinib [abstract]. <i>Ann Oncol</i> . 2012;23(Suppl 11): xi146–77. doi:10.1093/annonc/mds573
Gongjin-dan: minimal change disease and acute focal tubulointerstitial nephritis (serious)	Lee K-H, Jeong H-S, Rhee H. A patient with minimal change disease and acute focal tubulointerstitial nephritis due to traditional medicine: a case report and small literature review. <i>Explore (NY)</i> . 2014;10(5):319–23. doi:10.1016/j.explore.2014.06.001
Ipilimumab: dermatomyositis (serious)	Ali SS, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic t-lymphocyte antigen 4 blockade. <i>JAMA Dermatol</i> . 2015;151(2):195–9. doi:10.1001/jamadermatol.2014.2233
Octreotide: hypothermia (serious)	Kaur D, Singh G. Feeling cold with octreotide [abstract]. <i>Chest</i> . 146(4 Suppl):261A. doi:10.1378/chest.1995019
Piroxicam: DRESS syndrome (serious)	Sondes B, Wafa H, Hatem BA, et al. Severe acute hepatitis induced by a DRESS syndrome to piroxicam. <i>Tunis Med</i> . 2014;94(6):417. http://www.latunisiemedicale.com/article-medicale-tunisie_2578_en
Prasugrel: bleeding and cardiac tamponade (serious)	Dalén M, Ivert T, Lindvall G, et al. Prasugrel-related late cardiac tamponade after coronary artery bypass surgery in a patient with a recently implanted bare metal stent. <i>J Cardiothorac Vasc Anesth</i> . 2013;27(5):e57–8. doi:10.1053/j.jvca.2013.05.001

DRESS drug rash with eosinophilia and systemic symptoms